Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (221-230 of 330) with videos related to

Pageof 33
Sort By:
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Nature Communications|October 25, 2024
Osteopontin is a therapeutic target that drives breast cancer recurrenceYu Gu, Tarek Taifour, Tung Bui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerMarla Lipsyc-Sharf, Elza C de Bruin, Katheryn Santos, et al.
NPJ Breast Cancer|February 13, 2026
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancerPaolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Cancer|December 15, 2020
Perceptions of patients with early stage breast cancer toward research biopsiesDavinia S Seah, Jose Pablo Leone, Thomas H Openshaw, et al.
Nature Communications|March 20, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialJorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain MetastasesSheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
Journal of Neuro-Oncology|July 26, 2014
Local control after fractionated stereotactic radiation therapy for brain metastasesSelvan Rajakesari, Nils D Arvold, Rachel B Jimenez, et al.
Pageof 33

Showing results (221-230 of 330) with videos related to

Sort By:
Pageof 33
Breast Cancer Research : BCR|December 1, 2020
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E Emblem, Michelle Weitz, et al.
Nature Communications|October 25, 2024
Osteopontin is a therapeutic target that drives breast cancer recurrenceYu Gu, Tarek Taifour, Tung Bui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerMarla Lipsyc-Sharf, Elza C de Bruin, Katheryn Santos, et al.
NPJ Breast Cancer|February 13, 2026
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancerPaolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Cancer|December 15, 2020
Perceptions of patients with early stage breast cancer toward research biopsiesDavinia S Seah, Jose Pablo Leone, Thomas H Openshaw, et al.
Nature Communications|March 20, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialJorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain MetastasesSheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
Journal of Neuro-Oncology|July 26, 2014
Local control after fractionated stereotactic radiation therapy for brain metastasesSelvan Rajakesari, Nils D Arvold, Rachel B Jimenez, et al.
Pageof 33